Bioptamers

Bioptamers develops aptamer-based personalized molecules that identify cancer cells and deliver therapeutic interventions with precision. The company says its synthetic approach is designed to be more efficient, scalable, and lower-cost than monoclonal antibodies, antibody-drug conjugates, and cellular or gene therapies. It collaborates with universities, private companies, and hospitals to translate the platform into clinical outcomes, industrializing synthetic molecules around a targeted delivery system for chemical, radiation, and immunological therapies.